<DOC>
	<DOCNO>NCT00333229</DOCNO>
	<brief_summary>Breast cancer osteoporosis two frequent disease woman . Estrogen may associate bone loss risk breast cancer potent effect mitotic activity breast epithelium bone turnover . This study ass safety efficacy Zoledronic acid 4 mg , give every 3 month 24 month , improve bone mineral density premenopausal woman hormone receptor negative breast cancer adjuvant chemotherapeutic treatment compare placebo . This study recruit patient United States .</brief_summary>
	<brief_title>A Study Zoledronic Acid Prevention Cancer Therapy-induced Bone Loss</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Female patient histologically confirm incident invasive breast cancer ( T14 ) evidence regional lymph node metastasis ( N0 ) distant metastasis ( M0 ) complete primary tumor resection axillary lymph node dissection le 90 day start study drug treatment . Hormone receptor status negative Patient premenopausal ( spontaneous regular menses premenopausal estradiol level ( &gt; 10ng/dL ) Patient receive adjuvant standard chemotherapy approve cytotoxic chemotherapeutic drug ( e.g . AC 46 cycle ) ( prior neoadjuvant CT allow ) Bone density study entry &gt; 2.5 TScore Prior treatment bisphosphonates estrogens treatment osteoporosis addition calcium vitamin D Severe physical psychological concomitant disease know concurrent , severe medical disorder jeopardize life patient immediate future ( e.g. , myocardial infarction previous six month , angina pectoris despite treatment , uncontrolled severe arterial hypertension , progressive cardiac respiratory failure ) Known hypersensitivity bisphosphonates Abnormal renal function Current active dental problem include infection teeth jawbone ( maxilla mandibular ) ; dental fixture trauma , current prior diagnosis osteonecrosis jaw ( ONJ ) , expose bone mouth , slow healing dental procedure recent ( within 6 week ) plan dental jaw surgery ( e.g . extraction , implant )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>premenopausal</keyword>
	<keyword>Bone Mineral density</keyword>
	<keyword>Cancer therapy induce bone loss</keyword>
	<keyword>zoledronic acid</keyword>
</DOC>